Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
EyePoint Pharmaceuticals Price Target Announced at $15.00/Share by Jefferies
Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15
Outperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu Developments
EyePoint Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $29
J.P. Morgan Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $29
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)
Optimistic 'Buy' Rating for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Prospects
Buy Rating Justified by EyePoint Pharmaceuticals' Strong Financials and Promising DURAVYU Trials
EyePoint Pharmaceuticals Earns Buy Rating on Duravyu's Promising Efficacy and Safety Profile
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target
EyePoint Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target
EyePoint Pharmaceuticals Analyst Ratings
EyePoint Pharmaceuticals Analyst Ratings
JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Phase 3 Trials and FDA Alignment
HC Wainwright & Co. : The EyePoint Pharmaceuticals (EYPT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $30.00.
EyePoint Pharmaceuticals Analyst Ratings